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Background: Stereotactic ablative radiotherapy (SABR) can achieve excellent local control rates in early-stage non-
small cell lung cancer (NSCLC) and has emerged as a standard treatment option for patients who cannot undergo
surgery or those with isolated recurrences. However, factors that may predict toxicity or survival are largely
unknown. We sought here to identify predictors of survival and pneumonitis after SABR for NSCLC in a relatively
large single-institution series.
Methods: Subjects were 130 patients with stage I NSCLC treated with four-dimensional computed tomography (4D
CT) –planned, on-board volumetric image–guided SABR to 50 Gy in 4 fractions. Disease was staged by positron
emission tomography/computed tomography (PET/CT) and scans were obtained again at the second follow-up
after SABR.
Results: At a median follow-up time of 26 months, the 2-year local control rate was 98.5%. The median overall
survival (OS) time was 60 months, and OS rates were 93.0% at 1 year, 78.2% at 2 years, and 65.3% at 3 years. No
patient experienced grade 4–5 toxicity; 15 had radiation pneumonitis (12 [9.3%] grade 2 and 3 [2.3%] grade 3).
Performance status, standardized uptake value (SUV)max on staging PET/CT, tumor histology, and disease operability
were associated with OS on univariate analysis, but only staging SUVmax was independently predictive on
multivariate analysis (P= 0.034). Dosimetric factors were associated with radiation pneumonitis on univariate
analysis, but only mean ipsilateral lung dose ≥9.14 Gy was significant on multivariate analysis (P= 0.005).
Conclusions: OS and radiation pneumonitis after SABR for stage I NSCLC can be predicted by staging PET SUVmax
and ipsilateral mean lung dose, respectively.
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Lung cancer is the leading cause of cancer death
throughout the world and accounts for 28% of all cancer
deaths in the United States [1]. Approximately 15%–20%
of patients with non-small cell lung cancer (NSCLC)
present with early or localized disease that could be trea-
ted surgically [2,3]. Stereotactic ablative radiotherapy
(SABR), also known as stereotactic body radiotherapy
(SBRT), can achieve local control rates exceeding 90% as
well as promising survival rates in such cases when a
biologically effective dose (BED) of more than 100 Gy is
delivered to the planning target volume (PTV) [3-11].
SABR has emerged as a standard treatment option for
stage I disease in patients who cannot undergo surgery
for medical reasons [3-7] and for isolated recurrences of
NSCLC [6,12,13]. However, the information about fac-
tors that may predict survival and pneunonitis after
SABR is limited because of the heterogeneity of the
patients and dose regimens [13-19].
In this report, we reported clinical outcome and used
long-term follow-up data to identify potentially predict-
ive factors for survival and pneumonitis among 130
patients with stage I NSCLC treated with SABR to




We retrospectively analyzed 130 patients who had been
prospectively enrolled in either a phase II clinical proto-
col on image-guided SABR (n = 46) or in our SABR pro-
gram (n = 84) according to the same protocol guidelines
at The University of Texas MD Anderson Cancer Center
between February 2005 and December 2009. Reasons for
not being enrolled in the phase II protocol included pa-
tient or insurance refusal, not having had the required
brain magnetic resonance imaging (MRI) or computed
tomography (CT), or not having signed the protocol-
specific informed consent forms within the required
time. All patients provided written informed consent to
participate. Eligibility criteria included cytologically or
biopsy-proven stage I NSCLC (T <5 cm, N0, M0) and
inability or lack of desire to undergo surgery. Criteria for
medical inoperability were having a baseline forced ex-
piratory volume in 1 second (FEV1) or lung diffusion
capacity <40% of predicted values or severe diabetes
mellitus, cardiovascular disease, cerebral disease, or pul-
monary hypertension. Thirty-four patients whose disease
was considered borderline operable by thoracic surgeons
had declined surgery. Disease in all patients was staged
with chest CT and positron emission tomography (PET)/
CT (Discovery ST; GE Healthcare, Milwaukee, WI)
within 3 months before SABR and follow ups. The PET/
CT scan condition was described previously (26). Lesionswithin 2 cm of the bronchial tree or mediastinal struc-
tures were considered central; all others were considered
peripheral.
Treatment planning
Techniques for patient immobilization and treatment
planning are described elsewhere [6,12]. Briefly, patients
were immobilized while supine with a customized vac-
uum immobilization bag extending from the head to the
pelvis. Four-dimensional (4D) CT images were obtained
in all cases. Gross tumor volumes (GTVs) were deli-
neated by using maximum intensity projection of 4D CT
and modified by visual verification at different breathing
phases. The path of movement of the GTV during the
respiratory cycle was the internal gross tumor volume
(iGTV) [20]. The clinical target volume (CTV) was cre-
ated by expanding the iGTV by 8 mm isotropically, with
borders edited clinically. A 3-mm margin was added to
CTV to account for set-up errors, thereby creating the
PTV. No additional margins were used between the
PTV and the block edge. Three-dimensional conformal
SABR plans were optimized using 6 to 12 coplanar or
non-coplanar 6-MV photon beams. SABR was pre-
scribed to a dose of 50 Gy to the PTV between the 75%
and 90% isodose lines, which had been created via Pin-
nacle calculation algorithms with heterogeneity correc-
tion, and delivered in 4 fractions over 4 consecutive
days. Typically, the lower prescription isodose line was
chosen when the proximity of critical normal structures
mandated a compromise to the PTV, and therefore a
higher dose to the tumor center and sharper dose gradi-
ents were required. Normal tissue dose-volume con-
straints were based on BED calculations and our
previous clinical findings of the toxicity of SABR
[6,12,21] and are shown in Table 1. Violations to the
constraints for the spinal cord, esophagus, and brachial
plexus were not allowed; constraints on other normal
tissues were judged on the basis of clinical target cover-
age. Typically, when the tumor was close to a critical
structure, a compromise in PTV coverage was consid-
ered acceptable. In any situation, however, the iGTV
plus a margin of 5 mm was required to receive at least
95% of the prescribed dose. Patients with lesions very
close/ abutting to critical structures and whose normal
tissue dose volume constraints can’t be achieved were
treated with different dose regimens. Day-to-day varia-
tions in patient placement were minimized by volumet-
ric imaging of the treatment couch with either a CT-on-
rails or a cone-beam CT system.
Follow-up
Follow-up care consisted of CT imaging and clinical
examination every 3 months for the first 2 years after
SABR, every 6 months for the third year, and annually
Table 1 Critical organ dose-volume limits for stereotactic
ablative radiotherapy to 50 Gy given in 4 fractions
Organ, Limit, and Volume Maximum dose limits
Esophagus
Dmax 35 Gy
≤ 1 cm3 30 Gy
≤ 5 cm3 20 Gy
Brachial plexus
Dmax 40 Gy
≤ 1 cm3 35 Gy
≤ 5 cm3 30 Gy
Trachea
Dmax 45 Gy
≤ 1 cm3 35 Gy
≤ 5 cm3 30 Gy
Main bronchus and bronchial tree
≤ 1 cm3 40 Gy
≤ 5 cm3 35 Gy
Heart
≤ 1 cm3 40 Gy
≤ 5 cm3 35 Gy
Total lung volume*
V20 Gy(RBE) < 20% of total lung volume
V10 Gy(RBE) < 30% of total lung volume
V5 Gy(RBE) < 40% of total lung volume
Major vessels
Dmax 45 Gy
≤ 1 cm3 40 Gy
≤ 5 cm3 35 Gy
Skin
≤ 1 cm3 35 Gy
≤ 5 cm3 30 Gy
Chest wall
≤ 10 cm3 45 Gy
≤ 30 cm3 35 Gy
Spinal cord
Dmax 25 Gy
≤ 5 cm3 20 Gy
*Defined as right plus left lungs minus the gross tumor volume.
Table 2 Patient characteristics (n = 130)










Gross tumor volume, cm3
Median 9.6
Range 0.7–51.47













0 or 1 81 (62)
2 or 3 49 (38)
Lung cancer stage
IA (T1) 112 (86)
IB (T2) 18 (14)
Lung cancer histology
Squamous cell carcinoma 36 (28)
Adenocarcinoma 58 (45)
NSCLC not specified 36 (28)
Disease status





Abbreviations: FEV1, forced expiratory volume in 1 second; PET, positron
emission toography; SUVmax, maximum standardized uptake value; COPD,
chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology
Group; NSCLC, non-small cell lung cancer;
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deoxyglucose (FDG) PET scans at MD Anderson for dis-
ease staging and at the first or second follow-up visit
(median interval 4.3 months, range 2–7.6 months; the
wide range reflected unexpectedly interrupted follow-up)
and as clinically indicated thereafter. Rates and times of
overall survival (OS), progression-free survival (PFS),
local failure-free survival (LFFS), distant metastasis-free
Number of Patients at Risk:     
 OS                
 130               119                      62                       28                       13                         5 
 PFS               
 130               100                      49                       24                       11                         5 
Figure 1 Overall survival (OS) and progression-free survival (PFS) for 130 patients treated with stereotactic ablative radiotherapy
(SABR) for stage I NSCLC.
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tant metastasis were calculated from the date of comple-
tion of SABR to the last available follow-up. The time of
recurrence was the time at which the first image (PET/
CT or CT) showed abnormalities. Local failure was
defined as progressive abnormalities on CT images
corresponding to one or more FDG-avid lesions on
PET scans; positive biopsy findings within the PTV
plus a 1-cm margin; or lesions that appeared in the
same lobe after SABR. Recurrence appearing in differ-
ent lobes was scored as distant metastasis. Regional
failure was defined as intrathoracic lymph node relapse
outside the PTV. Toxicities, including RP, were scored
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events v3.0.
Statistical analyses
Data were analyzed with SAS (SAS Institute, Cary, NC)
statistical software, version 9.2. To analyze predictive
factors for OS, PFS, LFFS, and DMFS after SABR, con-
tinuous variables such as age, FEV1, maximum standar-
dized uptake value (SUVmax) on staging PET scans, and
GTV were discretely divided at the sample median and
then analyzed as nominal categorical variables. We used
the Kaplan-Meier method to estimate survival curves
and the log-rank test to compare the curves. P values <
0.05 were considered statistically significant. Character-
istics found to be significant by univariate analysis werethen entered in multivariable Cox proportional hazards
regression analysis.
To analyze predictive factors for RP, continuous vari-
ables such as age, FEV1, GTV, PTV, and dosimetric data
were divided at the medians and analyzed as nominal
categorical variables. Total lung volume was defined as
right plus left lungs minus the GTV, and ipsilateral lung
was defined as the lung containing the lesion to be trea-
ted minus the GTV. Comparisons were made with two-
sided Pearson’s chi-square tests. P values <0.05 were
considered statistically significant. Characteristics found
to be significant by univariate analysis were then entered
in a stepwise multiple binary logistic regression analysis
to identify independent predictive factors.
Results
Patient characteristics, survival, and patterns of failure
after SABR
Characteristics of the 130 patients treated with SABR
are listed in Table 2. At a median follow-up time of
26 months (range, 6–78 months), the median OS time
for all patients was 60 months (55 months for patients
with medically inoperable disease vs. >60 months [not
reached] for those with borderline operable disease).
One patient developed local failure concurrent with dis-
tant metastasis, and one patient developed isolated local
failure that was salvaged surgically. At 2 years, the
local control rate was 98.5%; the regional lymph node
Table 3 Univariate analysis of predictive factors for
overall and progression-free survival
Overall Survival Progression-Free Survival
Characteristic HR (95% CI) P valueHR (95% CI) P Value
Age, years
≥ 74 1
< 74 1.87 (0.93–3.78) 0.080 1.42 (0.83–2.44) 0.196
Sex
Male 1
Female 0.93 (0.48–1.82) 0.875 0.86 (0.51–1.47) 0.588
COPD stage
0–II 1
III–IV 0.75 (0.37-1.54) 0.413 0.66 (0.37-1.17) 0.594
History of other type of cancer
Yes 1
No 1.55 (0.78–3.09) 0.211 1.29 (0.74–2.24) 0.374
ECOG performance status
0–1 1
2–3 2.03 (1.04–3.95) 0.037 1.68 (0.99–2.85) 0.050
Lung cancer stage
IA (T1) 1
IB (T2) 1.28 (0.53–3.08) 0.586 1.11 (0.54–2.27) 0.776
Lung cancer histology
Non-squamous 1
Squamous 1.16 (1.01–1.34) 0.043 1.09 (0.97–1.22) 0.173
Staging PET SUVmax
< 6.2 1
≥ 6.2 2.10 (1.01-4.33) 0.028 1.81 (1.05–3.10) 0.032
Gross tumor volume, cm3
< 9.6 1
≥ 9.6 1.55 (0.79–3.05) 0.204 1.42 (0.84–2.42) 0.195
Disease status
Medically inoperable 1
Operable 0.36 (0.14–0.94) 0.036 0.51 (0.26–1.02) 0.055
Tumor location
Peripheral 1
Central 0.97 (0.34–2.76) 0.954 0.89 (0.35–2.25) 0.809
Radiation pneumonitis
No 1
Yes 1.19 (0.65–2.16) 0.571 0.92 (0.43–1.94) 0.819
Abbreviations: HR, hazard ratio; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group;
PET, positron emission tomography; SUVmax, maximum standardized uptake
value.
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regional lymph node recurrence rate was 6.9% (9/130).
Thirty patients (23.1%) developed DM, making it the dom-
inant pattern of treatment failure. Overall and progression-
free survival rates for all patients are illustrated in Figure 1.
OS rates were 93.0% at 1 year, 78.2% at 2 years, and 65.3%
at 3 years; the corresponding PFS rates were 78.4%, 60.5%,
and 55.0%. With regard to disease control, LFFS rates were
93.7% at 1 year, 88.8% at 2 years, and 88.8% at 3 years; the
corresponding DMFS rates were 89.1%, 79.4%, and 73.1%.
Toxicity associated with SABR
No patient experienced grade 4 or 5 toxicity, even those
with centrally located lesions. Chest wall pain was experi-
enced by 12 patients (11 [8.5%] grade 2 and 1 [0.8%]
grade 3), with median time to onset 8 months after SABR
(range 0–27 months). Eight patients (6.2%) had grade 2
or 3 dermatitis (median onset time 2 months, range
0–10 months). Fifteen patients developed RP (12 [9.2%]
grade 2 and 3 [2.3%] grade 3), with median time to onset
4 months (range 1–11 months). Only 2 patients (1.5%)
developed esophagitis (both grade 1) with the esophageal
dose-volume constraints used here. No definitive radiation-
induced cardiovascular toxicity was noted.
Predictors of OS and PFS after SABR
Next we explored whether SUVmax or other variables
could predict clinical outcomes after SABR for stage I
disease. Univariate analysis revealed that staging PET
SUVmax (dichotomized at the median 6.2, P= 0.028),
Eastern Cooperative Oncology Group (ECOG) perform-
ance status (P= 0.037), tumor histology (P= 0.043), and
whether the disease was considered medically operable
or not (P= 0.036) were significantly associated with OS
(Table 3); performance status and staging PET SUVmax
were also associated with PFS after SABR. Multivariate
Cox regression analysis showed that staging PET SUV-
max was the only independent significant predictor of OS
(hazard ratio [HR] 2.15; 95% confidence interval [CI]
1.06–4.34; P= 0.034): patients whose PET SUVmax at sta-
ging was less than the median 6.2 had higher rates of
long-term OS than did those with staging PET SUVmax
≥6.2 (Figure 2, P= 0.034). No significant predictors were
identified for LFFS and DMFS.
Risk factors for grade 2–3 RP
Univariate analysis of patient characteristics and dosi-
metric factors dichotomized at the medians (Table 4)
revealed that many dosimetric variables (lung volumes
receiving anywhere from 5 Gy to 40 Gy and mean lung
doses [MLDs]) were associated with the incidence of
grade 2–3 RP (P < 0.05) but that other patient character-
istics (e.g., FEV1, tumor location, performance status, and
GTV) were not. Multivariate binary logistic regressionanalysis with stepwise selection of variables found to be
significant in univariate analysis showed that only an MLD
to the ipsilateral lung ≥9.14 Gy (the median value) was
associated with grade 2–3 RP (odds ratio [OR] 18.86; 95%
Number of Patients at Risk:     
 SUV<6.2         
    62                  59                        31                        14                         6                           3 
 SUV 6.2         
    68                  53                        28                        11                         4                           1 
Figure 2 Overall survival according to maximum standardized uptake value (SUVmax) on staging PET/CT scans.
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Cox regression analysis to take onset time of pneumonitis
into consideration, ipsilateral lung V40 become the most
significant predictor for grade 2–3 RP, indicating high dose
(40 Gy) may be correlated with grade 2–3 RP developed
within certain time after SABR.
Discussion
We found that SABR to a dose of 50 Gy delivered in 4
fractions (BED 112.5 Gy) produced a 2-year local con-
trol rate of 98.5%, a median OS time of 60 months,
and minimal toxicity (minimal grade 3 and no grade 4
or 5). SUVmax on the staging PET/CT scan was the
only predictor of OS, with SUVmax less than the me-
dian 6.2 being associated with better survival. The
MLD to the ipsilateral lung (i.e., the lung containing
the lesion to be treated, minus the GTV) was the only
significant predictor of grade 2 or 3 RP. Among 130
patients, only two (<2%) experienced LF, one of which
occurred simultaneously with DM. The thoracic lymph
node recurrence rate of 8.5% was consistent with most
reported findings [3-11], and DM remained the dom-
inant pattern of failure. This finding, common in other
studies as well [3-7,9], underscores the need for novel
systemic treatments to reduce the incidence of distant
failure. Molecular markers may also be helpful for
identifying patients who may benefit from adjuvant
chemotherapy.Having other predictive tools in addition to traditional
factors such as age, disease stage, performance status,
tumor histology, and comorbidities to predict outcome be-
fore therapy is begun would be valuable both for the
choice of initial treatment and for identifying which
patients might benefit from additional systemic therapy.
Several surgical series [22-25] showed that pretreatment
SUVmax had predictive value in stage I NSCLC treated
surgically; one of these studies, an analysis of 136 patients,
found that a pretreatment SUVmax >5.5 predicted worse
recurrence and survival [23]. However, information on
SUV and SABR remains very limited at this time
[14-16,26]. Hoopes et al. [14] retrospectively evaluated
the predictive value of PET SUVmax in a prospective phase
I/II dose escalation clinical trial in which SABR was given
to 58 patients at doses of 24 to 72 Gy in 3 fractions. Local
control rates in that trial ranged from <70% to >95% for
the various dose groups, and pretreatment PET SUVmax
was not found to predict local control or survival. Another
retrospective study by Burdick and colleagues [16] showed
that pretreatment SUVmax did not predict regional failure,
distant failure, or survival; however, the 72 patients in that
study had also been treated with a wide range of radiation
doses (60 Gy in 3 fractions, 50 Gy in 5 fractions, or 50 Gy
in 10 fractions), and only 68.1% of patients had had
biopsy-proven NSCLC.
The relative strengths of our study were our relatively
large population (n = 130) and our inclusion of only
Table 4 Univariate analysis of patient and dosimetric characteristics and risk of radiation pneumonitis (n = 130)
Characteristic Grade 0–1 RP Grade 2–3 RP P Value
No. of Patients (%) No. of Patients (%)
Sex 0.882
Male 59 (51.3) 8 (53.3)
Female 56 (48.7) 7 (46.7)
Age 0.310
≥74 years 62 (53.9) 6 (40.0)
<74 years 53 (46.1) 9 (60.0)
COPD stage 0.154
0–II 62 (53.9) 11 (73.3)
III–IV 53 (46.1) 4 (26.7)
History of other type of cancer 0.440
Yes 34 (29.6) 3 (20.0)
No 81 (70.4) 12 (80.0)
ECOG score before SABR 0.711
0–1 71 (61.7) 10 (66.7)
2–3 44 (38.3) 5 (33.3)
Gross tumor volume, cm3 0.375
≥9.6 55 (47.8) 9 (60.0)
<9.6 60 (52.2) 6 (40.0)
Planning target volume, cm3 0.151
≥73.2 54 (47.0) 10 (66.7)
<73.2 61 (53.0) 5 (33.3)
Tumor location 0.471
Peripheral 106 (92.2) 13 (86.7)
Central 9 (7.8) 2 (13.3)
Total lung volume*
V5 < 0.001
≥ 20.2% 51 (44.3) 14 (93.3)
< 20.2% 64 (55.7) 1 (6.7)
V10 < 0.001
≥ 14.3% 51 (44.3) 14 (93.3)
< 14.3% 64 (55.7) 1 (6.7)
V15 0.003
≥ 11.0% 52 (45.2) 13 (86.7)
< 11.0% 63 (54.8) 2 (13.3)
V20 0.055
≥ 8.5% 54 (47.0) 11 (73.3)
< 8.5% 61 (53.0) 4 (26.7)
V25 0.055
≥ 6.4% 54 (47.0) 11 (73.3)
< 6.4% 61 (53.0) 4 (26.7)
V30 0.003
≥ 5.0% 52 (45.2) 13 (86.7)
< 5.0% 63 (54.8) 2 (13.3)
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Table 4 Univariate analysis of patient and dosimetric characteristics and risk of radiation pneumonitis (n = 130)
(Continued)
V35 0.003
≥ 3.9% 52 (45.2) 13 (86.7)
< 3.9% 63 (54.8) 2 (13.3)
V40 0.013
≥ 3.1% 53 (46.1) 12 (80.0)
< 3.1% 62 (53.9) 3 (20.0)
Mean dose to total lung volume 0.013
≥ 5.05 Gy 53 (46.1) 12 (80.0)
< 5.05 Gy 62 (53.9) 3 (20.0)
Ipsilateral lung volume†
V5 < 0.001
≥ 37.7% 51 (44.3) 14 (93.3)
< 37.7% 64 (55.7) 1 (6.7)
V10 < 0.001
≥ 28.5% 51 (44.3) 14 (93.3)
< 28.5% 64 (55.7) 1 (6.7)
V15 < 0.001
≥ 21.9% 51 (44.3) 14 (93.3)
< 21.9% 64 (55.7) 1 (6.7)
V20 < 0.001
≥ 16.9% 51 (44.3) 14 (93.3)
< 16.9% 64 (55.7) 1 (6.7)
V25 0.003
≥ 13.1% 52 (45.2) 13 (86.7)
< 13.1% 63 (54.8) 2 (13.3)
V30 0.013
≥ 10.4% 53 (46.1) 12 (80.0)
< 10.4% 62 (53.9) 3 (20.0)
V35 0.003
≥ 8.1% 52 (45.2) 13 (86.7)
< 8.1% 63 (54.8) 2 (13.3)
V40 0.013
≥ 6.3% 53 (46.1) 12 (80.0)
< 6.3% 62 (53.9) 3 (20.0)
Mean dose to ipsilateral lung volume < 0.001
≥9.14 Gy 51 (44.3) 14 (93.3)
<9.14 Gy 64 (55.7) 1 (6.7)
* Defined as right plus left lungs minus the gross tumor volume.
† Defined as the lung containing the lesion to be treated, minus the gross tumor volume.
Abbreviations: RP, radiation pneumonitis; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; SABR, stereotactic ablative
radiotherapy; Vx, volume of lung receiving ≥x Gy; GTV, gross tumor volume; MLD, mean lung dose.
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(T1N0M0, T <5 cm) NSCLC who had all been treated
with the same dose and who all underwent PET/CTboth before and after treatment at the same institution.
Our multivariate analyses indicated that having a staging
PET SUVmax level >6.2 predicted worse OS, and patients
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duce the likelihood of distant failure, which still remains
problematic. The predictive value of PET SUV may well
depend on the dose regimen used and perhaps some pa-
tient characteristics that we did not consider. Additional
studies are needed to validate our observations.
As we and others reported before, PET SUVs mea-
sured after SABR may be useful for detecting recurrence
(19, 26). In the current study, the staging PET SUVmax
levels for the 2 patients who developed local recurrence
were 1.8 and 6.5 but had increased to 9.8 and 7.2, re-
spectively, by 1 year after SABR. However, among the
other 128 patients who did not experience local recur-
rence in this study, 32 patients had a SUVmax >3 and 8
patients had a SUVmax >5 within 6 months after SABR.
Thus it seems likely that PET images obtained within
6 months after SABR may have a high false-positive rate.
Indeed, we and others have noted that PET images with
SUV >5 more than 6–12 months after SABR could indi-
cate possible local recurrence, but biopsy is still recom-
mended for confirmation [−25, 26], particularly when
salvage surgery is planned [27].
The most common side effect of SABR in our study was
chest-wall pain (12 patients, or 9.3%). A previous study
from our group showed that limiting the chest-wall V30
to< 30 cm3 reduced the incidence of chest-wall pain to 5%
[21]. However, for lesions next to the chest wall, we rec-
ommend that >95% of the GTV plus a 5-mm margin re-
ceive at least the full prescribed dose, even if the chest-
wall dose exceeds 35 Gy to 30 cm3. In our practice, 35 Gy
to 50 cm3 is allowed for lesions close to the chest wall.
RP can be a severe or even fatal side effect of irradi-
ation for lesions within 2 cm of the bronchial tree trea-
ted with 54 Gy delivered in 3 fractions [4]. Reports of
dose-volume analyses in SABR-induced RP have been
limited [13,17,18,28-30]. Barriger and others reported
correlations between total lung MLD (<4 Gy vs. >4 Gy),
lung V20 (<4% vs. >4%) and grade 2–4 RP among
patients treated with SABR to total doses of 42–60 Gy
given in 8- to 20-Gy fractions [31]. Matsuo found the as-
sociation between V25 and symptomatic RP after SABR
(17) . With our dose regimen (50 Gy in 4 fractions), our
normal-tissue dose-volume constraints (Table 1), and
our use of 4D CT-based treatment planning and volu-
metric on-board image-guided SABR delivery, we did
not observe any grade 4–5 RP. We saw no difference in
RP between central versus peripheral lesions when nor-
mal tissue dose volume constraints were respected and
inappropriate cases were excluded, and only 3 patients
(2.3%) experienced grade 3 RP. Interestingly, only MLD
to the ipsilateral lung was significantly associated with
RP in multivariate analysis; among the 65 patients with
an ipsilateral MLD ≥9.14 Gy, 14 had grade 2–3 RP
(21.5%), whereas among the 65 with an ipsilateral MLD<9.14 Gy, only 1 (1.5%) had grade 2–3 RP (P < 0.001).
This finding is consistent with those of Guckenberger
and colleagues, who also reported a correlation between
irradiated ipsilateral lung volume and SABR-induced RP
[30]. In addition, ipsilateral V40 appears to be correlated
with grade 2–3 RP when the onset times of RP were
considered. The specific dose cutoffs may be different
using different dose regimens. Our cutoffs should be
considered only when the same or similar SABR dose
regimens are used. To minimize the MLD to the ipsilat-
eral lung, one should consider using optimal image guid-
ance to reduce the set-up margin; prescribing the dose
to the lower isodose line rather than the higher one; and
not using an additional margin between the PTV to the
block edge.
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